Physician profile
Mark B Schuster
NPI 1851595565
$4,034.53
in general payments reported to CMS, 2019-2025
29 companies · $376 in 2025
The $376 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $345 · 2020: $153 · 2021: $1,161 · 2022: $634 · 2023: $529 · 2024: $836 · 2025: $376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,700 · Education: $41.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,699.65 |
| Education | $41.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $724.99 | 2019-2025 | Veltassa |
| Opko Pharmaceuticals, LLC | $434.55 | 2019-2024 | Rayaldee |
| Astrazeneca Pharmaceuticals Lp | $406.62 | 2019-2025 | Farxiga, Lokelma |
| Bard Peripheral Vascular, INC. | $387.00 | 2020-2024 | Covera |
| Genzyme Corporation | $248.20 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $231.65 | 2022-2025 | Lupkynis |
| Fresenius USA Marketing, INC. | $187.11 | 2019-2025 | Velphoro, Velphoro |
| Calliditas Therapeutics US INC. | $168.33 | 2022-2024 | |
| Daiichi Sankyo INC. | $156.76 | 2019-2025 | Injectafer |
| Baxter Healthcare | $149.42 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $134.07 | 2019-2025 | Jynarque, Voyxact |
| Akebia Therapeutics INC | $114.77 | 2021-2025 | Vafseo, Auryxia |
| Bayer Healthcare Pharmaceuticals INC. | $103.12 | 2022-2024 | |
| Amgen INC. | $87.64 | 2021-2025 | Krystexxa, Parsabiv, Tavneos |
| Travere Therapeutics, INC. | $82.12 | 2023-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $65.03 | 2024-2025 | Ibsrela |
| Novo Nordisk INC | $58.95 | 2024 | Rivfloza |
| Novartis Pharmaceuticals Corporation | $54.89 | 2024-2025 | |
| Nevro Corp. | $34.60 | 2023 | Senza |
| Glaxosmithkline, LLC. | $33.40 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.87 | 2024 | Jardiance |
| Xeris Pharmaceuticals, INC. | $24.77 | 2021 | |
| Amicus Therapeutics, INC. | $24.31 | 2019 | |
| Ascendis Pharma Endocrinology INC | $18.19 | 2025 | Yorvipath |
| Shire North American Group INC | $14.97 | 2019 | |
| Alnylam Pharmaceuticals INC. | $14.71 | 2023 | Givlaari |
| Ultragenyx Pharmaceutical INC. | $14.69 | 2019 | |
| Mallinckrodt Hospital Products INC. | $13.86 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.94 | 2023 | Gattex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Schuster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.